期刊文献+

细胞周期素D1过度表达在非小细胞肺癌预后作用的Meta分析

Significance of Cyclin D1 Overexpression on the Prognosis of Non-Small Cell Lung Cancer: A Meta-Analysis
下载PDF
导出
摘要 目的探讨细胞周期素D1过度表达与非小细胞肺癌预后的关系。方法检索PubMed以及CNKI中文数据库中研究细胞周期素D1表达与非小细胞肺癌预后关系的文献,根据欧洲肺癌工作组提供的专门的评分标准对纳入的文献进行质量评估,收集每个文献的相对危险比及95%可信区间。应用Meta分析Dersimonian-Laird模型对文献进行定量综合分析。结果共入选12篇文献,累计病例1 987例,细胞周期素D1阳性982例,阳性率49%。对入选12篇文献进行一致性检验,Q值为31.35,P<0.005,文献具有异质性,合并相对危险比为0.96,95%可信区间为0.82~1.10,P=0.308。结论细胞周期素D1的过度表达与非小细胞肺癌的预后无关。 Objective To evaluate the correlation of Cyclin DI overexpression with the prognosis of non-small cell lung cancer by a meta-analysis. Methods Articles on the correlation of Cyclin D1 expression with the prognosis of non-small cell lung cancer were searched from PuhMed database and CNKI Chinese database, their methodology was assessed by a scale specifically designed by the European Lung Cancer Working Party (ELCWP), the HR(hazard ratio) and 95%CI (confidence interval) in every article were abstracted. The results of 12 studies were analyzed by Dersimonian-Laird method. Results 12 studies were allowed a meta-analysis of the survival results, the overall positive rate of Cyclin D1 was 49% among the cumulative 1 987 patients. The analysis for homogeneity(Q statistics test) showed that all eligible studies were with heterogeneity(Q=31.35 ,P〈0.005). The combined HR was 0.96 and 95%CI was 0.82- 1.10, P=0.308. Conclusion Cyclin D1 expression is not correlation with prognosis of non-small cell lung cancer.
出处 《循证医学》 CSCD 2008年第3期156-161,共6页 The Journal of Evidence-Based Medicine
关键词 非小细胞肺癌 细胞周期素D1 预后 META分析 non-small cell lung cancer Cyclin D1 prognosis meta-analysis
  • 相关文献

参考文献20

  • 1Steels E, Paesmans M, Berghmans T, et al. Role of p53 on the survival of patients with lung cancer as assessed by systematic review of the literature[J]. Eur Respir J, 2001,18: 705 -719.
  • 2Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints[J]. Star Med, 1998, 17(24) :2815-2834.
  • 3Dersimonian R, Laird NM. Meta-analysis in clinical trials[J]. Controlled Clin Trials, 1986,7 : 177-188.
  • 4Nishio M, Koshikawa T, Yatabe Y, et al. Prognostic significance of cyclin D1 and retinoblastorna expression in combination with p53 abnormalities in primary, resected nonsmall cell lung cancers [J]. Clin Cancer Res, 1997,3(7): 1051-1058.
  • 5Volm M, Koomagi R, Rittgen W. Clinical implications of cyclins, cyclin-dependent kinases, RB and E2F1 in squamouscell lung carcinoma [ J ]. Int J Cancer, 1998,79 (3) : 294-299.
  • 6Kawabuchi B, Moriyama S, Hironaka M, et al. p16 inactivation in small-sized lung adenocarcinoma: Its association with poor prognosis[J]. Int J Cancer, 1999,84( 1 ) :49-53.
  • 7Mishina T, Dosaka-Akita H, Kinoshita I, et al. Cyclin D1 expression in non-small-cell lung cancers: Its association with altered p53 expression, cell proliferation and clinical outcome [J]. Br J Cancer, 1999,80(8): 1289-1295.
  • 8Brambilla E, Moro D, Gazzeri S, et al. Alterations of expression of Rb, p16 (INK4A) and eyelin D1 in non-small cell lung carcinoma and their clinical significance [J]. J Pathol, 1999, 188(4) : 351-360.
  • 9Dosaka-Akita H, Hommura F, Mishina T, et al. A riskstratification model of non-small cell lung cancers using cyelin E, Ki-67, and ras p21 : Different roles of G1 cyclins in cell proliferation and prognosis [J]. Cancer Res, 2001,61(6): 2500-2504.
  • 10Jin M, Inoue S, Umemura T, et al. Cyclin D1, p16 and retinoblastoma gene product expression as a predictor for prognosis in non-small cell lung cancer at stages I and Ⅱ [J]. Lung Cancer, 2001,34(2) :207-218.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部